InSite Vision, Inc.
Business Strategy

Accelerating Opportunity

The U.S. Census Bureau projects that the population over the age of 65 will increase from 35 million in 1999 to approximately 70 million by the year 2030. We believe that this aging of the U.S. population, and similar trends in other developed countries, will contribute to increased demand for new and effective ophthalmic products.

InSite Vision's business strategy is focused on accelerating ophthalmic product opportunities that are consistent with our core competencies and allow us to address expanding needs in growing markets. We are addressing these opportunities in a variety of ways:

  • Internal development: We develop internal product candidates based on our technology platforms, while retaining the option of partnering with other biotechnology companies to complete the clinical development and/or commercialization of the product opportunity.
  • In-licensing: We license promising product candidates and technologies from academic institutions as well as other companies. However, we also develop product candidates for non-ophthalmic indications using either non-proprietary drugs or compounds developed by others.
  • Out-licensing: InSite Vision has proprietary technologies that offer significant therapeutic potential. These technologies are made available to collaborators with mutual interests who share our vision of creating unique therapeutic products of lasting value.
  • New intellectual property: We believe that emerging genomic research will provide alternatives to the methods and products currently used to provide eye care. Therefore, our ongoing participation in a variety of clinical research activities is founded in our long-term strategy related to this unique opportunity.

The number of Americans with age-related eye disease and the vision impairment that results from such conditions is expected to double within the next 30 years, according to a Prevent Blindness America report. Download "Vision Problems in the U.S."


Vision Statement
"Preservation of sight" was the driving force behind the founding of InSite Vision in 1987 and remains so today. We pursue that vision through the development of innovative technologies and products. Advancing the treatment of eye disease guides our resource investments and the search for more effective "solutions for sight." We are committed to providing these solutions to patients and physicians and, in doing so, building the long-term value of InSite Vision for our global shareholders and partners.